网站地图
首页 > CSCO动态 > ACT China III视频——2013第三届国际临床研究高级研修班

ACT China III视频——2013第三届国际临床研究高级研修班

作者: 来源: 发布时间:2014-02-17 14:22:04 今日访问/总访问:1|2261

 

11.22pm

 

1、Welcom andintroduction

 

2、the principalinvestigator's responsibilities in conducting biomarker driven clinical trials

Richard L. Schilsky

 

3、Phase I biomarkerdriven clinical trials:objectives,design,endpoints

Lillian L.Siu

 

4、Phase I trials oftargeted agent combinations

Jin Li

 

5、Pharmacokinetics,drug-target interactions, and identifying adverse events in phase I biomarkerdriven clinical trials

Lillian L.Siu

 

6、Paneldiscussion:Phase I biomarker driven clinical trials

 

11.23am

 

1、Development andvalidation of biomarkers as clinical tests

Lillian L.Siu

 

2、Biomarker-drivenPHASE II clinical trials

Richard L. Schilsky

 

3、Adaptive design andbiomarker-based Phase I, Phase II trials

J. Jack Lee

 

4、Do we need Phase II trials in the biomarkerdriven study era?

Yi-Long Wu

 

5、Panel discussion:Use of Phase II clinical trials in the era of biomarker driven research

 

11.23pm

 

1、Statistical considerationsfor Phase III biomarker driven trials, interim analusis, and data monitoring

J. Jack Lee

 

2、Panel discussion 1

 

3、Panel discussion 2

 

11.24am

 

1、 Disscus1

 

2、 Disscus2

 

3、 Opportunities and challenges in combining targeted therapies forbreast cancer

Bi-yun Wang

 

4、A multi center,randomized, phase II trial of MLN0128 versus placebo in 3rdlinetreatment of advanced NSCLC with wild-type EGFR/ALK

Qiang Nie

 

5、Phase I study ofipilimumab in patients with advanced nasopharyngeal cancer

Jun-ning Cao

 

6、Phase I clinicaltrial of MLN0128 combined with bevacizumab in solid tumors

Ji-fang Kong

 

7、Randomizedcontrolled phase II trial: efficiedcy and safety of MLN0128 in advanced gastriccancer

Hao Zhang

 

8、Closing remarks


感谢 北京金叶天盛公司 提供视频文件